Search
Elicio Therapeutics Inc
ELTXAdd to Watchlist
5.140USD
+1.230+31.46%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
91.49MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+31.46%
5 Days
+29.15%
1 Month
-57.59%
6 Months
-35.43%
Year to Date
-35.43%
1 Year
-33.42%
Key Figures
3.980Open
5.380High
2.38MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
13.39%Turnover Ratio
3.910Prev. Close
3.920Low
7.80MTurnover
LossP/E Static
55.93P/B
0.00%Div Yield TTM
-158.11%ROA
14.93052wk High
2.50Volume Ratio
-51.90MNet Profit
17.80MShares
-2.3679EPS TTM
--Beta
-1076.34%ROE
6.90052wk Low
37.34%Amplitude
100.00%Gross Margin
91.49MMarket Cap
-11.20Reward/Risk
5.89%Risk Rate
TradingKey Stock Score of Elicio Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Elicio Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 129 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.67.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Elicio Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Elicio Therapeutics Inc Highlights
StrengthsRisks
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Fairly Valued
The company’s latest PE is -1.65, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.79M shares, decreasing 18.49% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 14.96.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
20.667
Target Price
+428.56%
Upside Space
Elicio Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Elicio Therapeutics Inc Info
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Ticker SymbolELTX
CompanyElicio Therapeutics Inc
CEOConnelly (Robert)
Websitehttps://elicio.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52283.700
+29.400 (+0.06%)
29935.500
+136.200 (+0.46%)
7493.000
+17.500 (+0.23%)
15216.000
-139.000 (-0.91%)
69509.000
+24.000 (+0.04%)
6291.400
+16.000 (+0.26%)
67.544
-0.424 (-0.62%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4053.440
+22.670 (+0.56%)
FAQs
What is the current price of Elicio Therapeutics Inc (ELTX)?
The current price of Elicio Therapeutics Inc (ELTX) is 5.14.
What is the symbol of Elicio Therapeutics Inc?
The ticker symbol of Elicio Therapeutics Inc is ELTX.
What is the 52-week high of Elicio Therapeutics Inc?
The 52-week high of Elicio Therapeutics Inc is 14.93.
What is the 52-week low of Elicio Therapeutics Inc?
The 52-week low of Elicio Therapeutics Inc is 6.90.
What is the market capitalization of Elicio Therapeutics Inc?
The market capitalization of Elicio Therapeutics Inc is 91.49M.
Is Elicio Therapeutics Inc (ELTX) currently rated as Buy, Hold, or Sell?
According to analysts, Elicio Therapeutics Inc (ELTX) has an overall rating of Buy, with a price target of 20.67.
What is the Earnings Per Share (EPS TTM) of Elicio Therapeutics Inc (ELTX)?
The Earnings Per Share (EPS TTM) of Elicio Therapeutics Inc (ELTX) is -2.58.